Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study.

ABSTRACT: Degenerative eye diseases cause partial or complete blindness due to photoreceptor degeneration. Optogenetic gene therapy is a revolutionary technique combining genetics and optical methods to control the function of neurons. Due to the inherent risk of photochemical damage, the light intensity necessary to activate Opto-mGluR6 surpasses the safe threshold for retinal illumination. Conversely, red-shifted lights pose a significantly lower risk of inducing such damage compared to blue lights. We designed red-shifted Opto-mGluR6 photopigments with a wide, red-shifted working spectrum compared to Opto-mGluR6 and examined their excitation capability in vitro. ROM19, ROM18 and ROM17, red-shifted variants of Opto-mGluR6, were designed by careful bioinformatics/computational studies. The predicte

SUBMITTER: Shamsnajafabadi H 

PROVIDER: S-EPMC11500960 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature